Literature DB >> 27009297

Anaemia secondary to erythropoietin resistance: important predictor of adverse outcomes in chronic obstructive pulmonary disease.

Rahul Kumar Sharma1, Shibdas Chakrabarti1.   

Abstract

PURPOSE: Anaemia is increasingly being linked to chronic obstructive pulmonary disease (COPD) as comorbidity with erythropoietin resistance secondary to chronic inflammation is hypothesised to have some role. This study purported to evaluate the occurrence of anaemia in COPD and its association with inflammatory markers, erythropoietin levels, severity and exacerbations of COPD.
METHODS: Two hundred patients with COPD (90% men, mean age 62.4±8.33 years) were enrolled and subjected to detailed clinical and laboratory evaluation, including complete blood count, erythropoietin levels, C-reactive protein (CRP), pulmonary function test, blood gas analysis and chest X-ray. Severity of COPD was defined on the basis of forced expiratory volume in 1 s according to GOLD guidelines.
RESULTS: Anaemia was diagnosed in 14% of patients (n=28, predominantly normocytic normochromic type (92.8%)) and polycythmia in 5% of patients (n=10). The prevalence of anaemia increased with increasing severity of COPD (stage 2: 8%, stage 3: 14.4% and stage 4: 17.2%; p=0.46). Serum erythropoietin was significantly higher in more advanced COPD, with mean levels being 30.2±6.5, 31.78±8.09 and 39.33±7.68 mIU/mL in stage 2, 3 and 4 respectively. Moreover erythropoietin levels inversely correlated with mean haemoglobin levels(r=-0.25), indicating erythropoietin resistance. CRP reactivity increased with increasing stage of disease in patients with anaemia (p=0.026). On follow-up, significant inverse correlation was observed between haemoglobin and COPD exacerbations (p<0.001).
CONCLUSIONS: Anaemia is a significant comorbidity of COPD with a negative prognostic impact on lung health. It can be ascribed to a state of systemic inflammation resulting in blunting of erythropoietin response with increasing severity of disease, leading to greater morbidity and hospitalisation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Anemia; Anemia of Chronic disease; C reactive protein; Chronic obstructive pulmonary disease; Erythropoietin resistance

Year:  2016        PMID: 27009297     DOI: 10.1136/postgradmedj-2015-133814

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: Results from a randomized comparative effectiveness research trial.

Authors:  Cheng-Liang Qian; Rong Fan
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

2.  Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model.

Authors:  Elizabeth Perez; Jonathan R Baker; Silvana Di Giandomenico; Pouneh Kermani; Jacqueline Parker; Kihwan Kim; Jianjun Yang; Peter J Barnes; Sophie Vaulont; Joseph M Scandura; Louise E Donnelly; Heather Stout-Delgado; Suzanne M Cloonan
Journal:  J Immunol       Date:  2020-09-21       Impact factor: 5.422

3.  Baseline Soluble Anti-erythropoietin Antibody Level Is an Independent Associated Factor for Follow-Up Erythropoietin Demand in Maintenance Dialysis Patients With End-Stage Renal Disease: A Prospective Cohort Study.

Authors:  Ying Zhang; Shi-Zhu Bian; Kun Yang; Yiqing Wang; Sha Tang; Weili Wang; Daihong Wang; Ling Nie; Jinghong Zhao
Journal:  Front Med (Lausanne)       Date:  2020-04-07

4.  Clinical Markers of Chronic Hypoxemia in Respiratory Patients Residing at Moderate Altitude.

Authors:  Rosario Fernández-Plata; Ireri Thirion-Romero; Karol J Nava-Quiroz; Gloria Pérez-Rubio; Sebastián Rodríguez-Llamazares; Midori Pérez-Kawabe; Yadira Rodríguez-Reyes; Selene Guerrero-Zuñiga; Arturo Orea-Tejeda; Ramcés Falfán-Valencia; Rogelio Pérez-Padilla
Journal:  Life (Basel)       Date:  2021-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.